GYRE GYRE THERAPEUTICS, INC.
8-K Current Report
Filed: March 2, 2026
Health Care
Pharmaceutical PreparationsGYRE THERAPEUTICS, INC. (GYRE) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items5 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 3.02: Unregistered Sales of Equity Securities
- Item 5.02: Departure/Election of Directors or Officers
- Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • Each preferred share converts into 5 shares of common stock post-stockholder approval of Conversion Proposal — significant dilution risk for common holders
- • Conversion blocked if holder's resulting ownership would exceed 0%–19.99% beneficial ownership threshold (set by each holder)
Item 3.02 · Unregistered Sales of Equity Securities
- • Item 3.02 covers unregistered securities sales — no details provided in this excerpt; refer to full filing for complete disclosure
Item 5.02 · Departure/Election of Directors or Officers
- • Two directors (Thomas Eastling, Songjiang Ma) resign; board shrinks from 9 to 7 directors per Merger Agreement terms
- • Songjiang Ma also vacates President role — dual leadership departure signals significant post-merger restructuring
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- • Certificate of Designation for Preferred Stock to be filed with Delaware Secretary of State, linked to a pending Merger transaction
- • Preferred Stock designation signals new share class creation — typically used to define liquidation preferences, voting rights, and conversion terms for deal consideration
Item 7.01 · Regulation FD Disclosure
- • Reg FD disclosure references investor presentation (Exhibit 99.2) and press release (Exhibit 99.1) — substantive content in those exhibits
- • Key pending events: stockholder vote on Conversion Proposal and closing of a Merger transaction
Other GYRE THERAPEUTICS, INC. 8-K Filings
Get deeper insights on GYRE THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.